Trials / Completed
CompletedNCT00089960
Study of AMG 706 in Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs)
An Open Label Study of AMG 706 in Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs) Who Developed Progressive Disease or Relapsed While on Imatinib Mesylate
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 138 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will determine the safety and effectiveness of AMG 706 in patients with advanced GIST.
Detailed description
Expanded Access: Amgen provides expanded access for this clinical trial. Contact the Amgen Call Center (866-572-6436) for more information.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AMG 706 | AMG 706 125 mg daily for 48 weeks, or until progressive disease or unacceptable toxicity. |
Timeline
- Start date
- 2004-10-01
- Primary completion
- 2006-06-01
- Completion
- 2008-06-01
- First posted
- 2004-08-20
- Last updated
- 2013-04-29
Source: ClinicalTrials.gov record NCT00089960. Inclusion in this directory is not an endorsement.